Rakovina Therapeutics Inc.

OTCPK:RKVT.F Stock Report

Market Cap: US$7.0m

Rakovina Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Mads Daugaard

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.1%
Management average tenureno data
Board average tenure3.7yrs

Recent management updates

Recent updates

CEO

Mads Daugaard

no data

Tenure

Dr. Mads Daugaard, Ph D., serves as Member of Scientific Advisory Board of Hexamer Therapeutics, Inc. He serves as the President, Chief Executive Officer and Chief Scientific Officer at Rakovina Therapeuti...

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Bacha
Executive Chairman3.8yrsCA$120.00k2.09%
$ 145.8k
Leonard Post
Member of Scientific Advisory Board3.7yrsno datano data
Michael Liggett
Independent Director3.8yrsCA$42.50kno data
Dennis Brown
Chairman of Scientific Advisory Board & Independent Director3.8yrsCA$35.00k0.69%
$ 48.3k
Alfredo De Lucrezia
Independent Director5.6yrsCA$39.00k5.77%
$ 403.1k
Artem Cherkasov
Senior AI1.1yrsno datano data
Wang Shen
Member of Scientific Advisory Board3.7yrsno datano data
Neil Sankar
Member of Scientific Advisory Board3.7yrsno datano data
Petra Hamerlik
Member of Scientific Advisory Board1.1yrsno datano data

3.7yrs

Average Tenure

64yo

Average Age

Experienced Board: RKVT.F's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/16 15:56
End of Day Share Price 2024/09/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rakovina Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution